{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T13:36:09Z","timestamp":1784122569262,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40121-021-00540-5","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T10:14:06Z","timestamp":1632910446000},"page":"2611-2623","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Tolerability and Adherence of Antiretroviral Regimens Containing Long-Acting Fusion Inhibitor Albuvirtide for HIV Post-Exposure Prophylaxis: A Cohort Study in China"],"prefix":"10.1007","volume":"10","clinical-trial-number":[{"clinical-trial-number":"chictr1900022881","registry":"10.18810\/chictr"}],"author":[{"given":"Jingmin","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanqun","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaokai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,29]]},"reference":[{"issue":"Suppl 3","key":"540_CR1","doi-asserted-by":"publisher","first-page":"S203","DOI":"10.1097\/QAD.0000000000002321","volume":"33","author":"M Mahy","year":"2019","unstructured":"Mahy M, Marsh K, Sabin K, et al. HIV estimates through 2018: data for decision-making. AIDS. 2019;33(Suppl 3):S203\u201311.","journal-title":"AIDS"},{"key":"540_CR2","unstructured":"Global HIV & AIDS statistics \u2014 2020 fact sheet | UNAIDS, https:\/\/www.unaids.org\/en\/resources\/fact-sheet. Accessed 6 May 2021."},{"key":"540_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ijid.2019.02.016","volume":"81","author":"YC Qiao","year":"2019","unstructured":"Qiao YC, Xu Y, Jiang DX, et al. Epidemiological analyses of regional and age differences of HIV\/AIDS prevalence in China, 2004\u20132016. Int J Infect Dis. 2019;81:215\u201320.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"540_CR4","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/CM9.0000000000000647","volume":"133","author":"ZY Wu","year":"2020","unstructured":"Wu ZY, Scott SR. Human immunodeficiency virus prevention strategies in China. Chin Med J (Engl). 2020;133(3):318\u201325.","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"540_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.21106\/ijma.311","volume":"8","author":"C Kouanfack","year":"2019","unstructured":"Kouanfack C, Meli H, Cumber SN, et al. Non-occupational HIV post-exposure prophylaxis: a 10-year retrospective review of data following sexual exposure from Yaounde Central Hospital, Cameroon. Int J MCH AIDS. 2019;8(2):138\u201345.","journal-title":"Int J MCH AIDS"},{"issue":"16","key":"540_CR6","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel. JAMA. 2020;324(16):1651\u201369.","journal-title":"JAMA"},{"issue":"12","key":"540_CR7","first-page":"867","volume":"57","author":"AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, & Chinese Center for Disease Control and Prevention","year":"2018","unstructured":"AIDS and Hepatitis C Professional Group, Society of Infectious Diseases, Chinese Medical Association, & Chinese Center for Disease Control and Prevention. Chinese guidelines for diagnosis and treatment of HIV\/AIDS. Chin J Intern Med. 2018;57(12):867\u201384.","journal-title":"Chin J Intern Med"},{"issue":"4","key":"540_CR8","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/QAI.0b013e31824a03b8","volume":"59","author":"KH Mayer","year":"2012","unstructured":"Mayer KH, Mimiaga MJ, Gelman M, et al. Raltegravir, tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59(4):354\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"540_CR9","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1093\/jac\/dkx062","volume":"72","author":"A Milinkovic","year":"2017","unstructured":"Milinkovic A, Benn P, Arenas-Pinto A, et al. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra\u00ae in combination with Truvada\u00ae for HIV post-exposure prophylaxis (MiPEP Trial). J Antimicrob Chemother. 2017;72(6):1760\u20138.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"540_CR10","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1093\/jac\/dkx246","volume":"72","author":"A Inciarte","year":"2017","unstructured":"Inciarte A, Leal L, Gonz\u00e1lez E, et al. Tenofovir disoproxil fumarate\/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. J Antimicrob Chemother. 2017;72(10):2857\u201361.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"540_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/QAI.0000000000001440","volume":"75","author":"K Mayer","year":"2017","unstructured":"Mayer K, Jones D, Oldenburg C, et al. Optimal HIV postexposure prophylaxis regimen completion with single tablet daily elvitegravir\/cobicistat\/tenofovir disoproxil fumarate\/emtricitabine compared with more frequent dosing regimens. J Acquir Immune Defic Syndr. 2017;75(5):535\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"540_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12879-016-2056-3","volume":"16","author":"N Valin","year":"2016","unstructured":"Valin N, Fonquernie L, Daguenel A, et al. Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis. BMC Infect Dis. 2016;16(1):718.","journal-title":"BMC Infect Dis"},{"key":"540_CR13","first-page":"157","volume":"8","author":"T Whitfield","year":"2016","unstructured":"Whitfield T, Torkington A, van Halsema C. Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV\/AIDS (Auckl). 2016;8:157\u201364.","journal-title":"HIV\/AIDS (Auckl)"},{"issue":"6","key":"540_CR14","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1093\/jac\/dkw042","volume":"71","author":"M Kovarova","year":"2016","unstructured":"Kovarova M, Swanson MD, Sanchez RI, et al. A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges. J Antimicrob Chemother. 2016;71(6):1586\u201396.","journal-title":"J Antimicrob Chemother"},{"key":"540_CR15","unstructured":"HPTN 083 study information. https:\/\/www.hptn.org\/research\/studies\/hptn083. Accessed 4 July 2021."},{"key":"540_CR16","unstructured":"HPTN 084 study information. https:\/\/www.hptn.org\/research\/studies\/hptn084. Accessed 4 July 2021."},{"issue":"3","key":"540_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032599","volume":"7","author":"H Chong","year":"2012","unstructured":"Chong H, Yao X, Zhang C, et al. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor. PLoS ONE. 2012;7(3): e32599.","journal-title":"PLoS ONE"},{"issue":"1","key":"540_CR18","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1128\/AAC.00976-09","volume":"54","author":"D Xie","year":"2010","unstructured":"Xie D, Yao C, Wang L, et al. An albumin-conjugated peptide exhibits potent anti-HIV activity and long in vivo half-life. Antimicrob Agents Chemother. 2010;54(1):191\u20136.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"540_CR19","first-page":"162","volume":"20","author":"MS Saag","year":"2012","unstructured":"Saag MS. New and investigational antiretroviral drugs for HIV infection: mechanisms of action and early research findings. Top Antivir Med. 2012;20(5):162\u20137.","journal-title":"Top Antivir Med"},{"issue":"24","key":"540_CR20","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1097\/CM9.0000000000001273","volume":"133","author":"B Su","year":"2020","unstructured":"Su B, Yao C, Zhao QX, et al. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study. Chin Med J (Engl). 2020;133(24):2919\u201327.","journal-title":"Chin Med J (Engl)"},{"issue":"6","key":"540_CR21","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1007\/s00268-020-05402-8","volume":"44","author":"J Yang","year":"2020","unstructured":"Yang J, Wei G, He Y, et al. Perioperative antiretroviral regimen for HIV\/AIDS patients who underwent abdominal surgery. World J Surg. 2020;44(6):1790\u20137.","journal-title":"World J Surg"},{"issue":"9","key":"540_CR22","first-page":"893","volume":"41","author":"S He","year":"2020","unstructured":"He S, Liu H, Yao Y, et al. The clinical effect of albuvirtide program in severe AIDS patients. Sichuan Med J. 2020;41(9):893\u20137.","journal-title":"Sichuan Med J"},{"key":"540_CR23","first-page":"1","volume":"8","author":"FL Xu","year":"2021","unstructured":"Xu FL, Pan NL, He KY, et al. Long-acting HIV fusion inhibitor albuvirtide is a safe and effective treatment in HIV patients with severe liver impairment, HBV co-infection and high HIV RNA copies. J HIV AIDS Infect Dis. 2021;8:1\u20139.","journal-title":"J HIV AIDS Infect Dis"},{"issue":"18","key":"540_CR24","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.3390\/ijerph17186881","volume":"17","author":"RC Santa-B\u00e1rbara","year":"2020","unstructured":"Santa-B\u00e1rbara RC, Hueso-Montoro C, Mart\u00edn-Salvador A, et al. Association between Sexual Habits and Sexually Transmitted Infections at a Specialised Centre in Granada (Spain). Int J Environ Res Public Health. 2020;17(18):6881.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"540_CR25","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/v13020228","volume":"13","author":"M Berruti","year":"2021","unstructured":"Berruti M, Riccardi N, Canetti D, et al. Injectable antiretroviral drugs: back to the future. Viruses. 2021;13(2):228.","journal-title":"Viruses"},{"key":"540_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12981-016-0091-1","volume":"13","author":"H Zhang","year":"2016","unstructured":"Zhang H, Jin R, Yao C, et al. Combination of long-acting HIV fusion inhibitor albuvirtide and LPV\/r showed potent efficacy in HIV-1 patients. AIDS Res Ther. 2016;13:8.","journal-title":"AIDS Res Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00540-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-021-00540-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-021-00540-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T14:18:23Z","timestamp":1636294703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-021-00540-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,29]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s40121-021-00540-5","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,29]]},"assertion":[{"value":"25 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}